Sanofi’s vaccines division launches Shan5

10 Nov 2014 Evaluate

Sanofi’s vaccines division -- Sanofi Pasteur -- has launched Shan5, its paediatric pentavalent vaccine developed and manufactured by its affiliate Shatha Biotechnic in India. The vaccine received prequalification status from Wold Health Organisation (WHO) in April 2014.

The launch of Shan 5 in India means that 27 million babies born annually in India will have access to vaccination to protect from five potentially deadly diseases. By launching the vaccine Shantha will be contributing to filling this immunisation gap for the benefit of babies and their parents.

The WHO prequalification helps Shantha secure the supply of  pentavalent combination vaccines in over 50 emerging and low-income countries.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

 

Sanofi India Share Price

6052.95 -28.20 (-0.46%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.